Mouse models in neurological disorders: Applications of non-invasive imaging

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 10, 2010, Pages 819-839

  Waerzeggers, Yannic ^a   Monfared, Parisa ^a   Viel, Thomas ^a   Winkeler, Alexandra ^a   Jacobs, Andreas H ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alzheimer's disease; Glioma; Mouse models; Neurodegeneration; Neuroimaging; Neurooncology; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DONEPEZIL; EPOXOMICIN; GALANTAMINE; MEMANTINE; OXIDOPAMINE; PARAQUAT; RIVASTIGMINE; ROTENONE;

ALZHEIMER DISEASE; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; APOPTOSIS; GENE MUTATION; GENE THERAPY; GLIOMA; HUMAN; NERVE DEGENERATION; NEURAL STEM CELL TRANSPLANTATION; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ANIMAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MODEL; MOUSE; NERVOUS SYSTEM DISEASES;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; NERVOUS SYSTEM DISEASES;

ANIMALIA;

EID: 77956064371     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.04.009     Document Type: Review

References (240)

1. Strome E.M., Doudet D.J. Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol. Imaging Biol. 2007, 9(4):186-195.
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20(4):415-455.
3. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
4. de la Fuente-Fernandez R., Calne D.B. Evidence for environmental causation of Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8(4):235-241.
5. Tolosa E., Wenning G., Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006, 5(1):75-86.
6. Bonifati V., Oostra B.A., Heutink P. Unraveling the pathogenesis of Parkinson's disease-the contribution of monogenic forms. Cell. Mol. Life Sci. 2004, 61(14):1729-1750.
7. Melrose H.L., Lincoln S.J., Tyndall G.M., Farrer M.J. Parkinson's disease: a rethink of rodent models. Exp. Brain Res. 2006, 173(2):196-204.
8. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2(3):484-494.
9. Fleming S.M., Fernagut P.O., Chesselet M.F. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2005, 2(3):495-503.
10. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984, 5(1):77-82.
11. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997, 48(6):1583-1588.
12. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277(3):1641-1644.
13. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179(1):9-16.
14. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56(1):149-162.
15. Kahle P.J. alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115(1):87-95.
16. Harvey B.K., Wang Y., Hoffer B.J. Transgenic rodent models of Parkinson's disease. Acta Neurochir. Suppl. 2008, 101:89-92.
17. Nagano-Saito A., Washimi Y., Arahata Y., Kachi T., Lerch J.P., Evans A.C., et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005, 64(2):224-229.
18. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004, 127(Pt 4):791-800.
19. Dagher A., Nagano-Saito A. Functional and anatomical magnetic resonance imaging in Parkinson's disease. Mol. Imaging Biol. 2007, 9(4):234-242.
20. Clarke C.E., Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur. J. Neurol. 2001, 8(6):573-577.
21. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64(2):208-215.
22. Au W.L., Adams J.R., Troiano A.R., Stoessl A.J. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res. Mol. Brain Res. 2005, 134(1):24-33.
23. Doudet D.J., Chan G.L., Holden J.E., McGeer E.G., Aigner T.A., Wyatt R.J., et al. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998, 29(3):225-232.
24. Melega W.P., Raleigh M.J., Stout D.B., DeSalles A.A., Cherry S.R., Blurton-Jones M., et al. Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys. Exp. Neurol. 1996, 141(2):318-329.
25. Schneider J.S., Lidsky T.I., Hawks T., Mazziotta J.C., Hoffman J.M. Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Brain Res. 1995, 672(1-2):112-117.
26. Hantraye P., Brownell A.L., Elmaleh D., Spealman R.D., Wullner U., Brownell G.L., et al. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism. NeuroReport 1992, 3(3):265-268.
27. Wullner U., Pakzaban P., Brownell A.L., Hantraye P., Burns L., Shoup T., et al. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT. Exp. Neurol. 1994, 126(2):305-309.
28. Brownell A.L., Jenkins B.G., Isacson O. Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. Biomed. Pharmacother. 1999, 53(3):131-140.
29. Brownell A.L., Canales K., Chen Y.I., Jenkins B.G., Owen C., Livni E., et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage 2003, 20(2):1064-1075.
30. Doudet D.J., Jivan S., Ruth T.J., Holden J.E. Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 2002, 44(3):198-202.
31. Hantraye P., Loc'h C., Tacke U., Riche D., Stulzaft O., Doudet D., et al. "In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates. Life Sci. 1986, 39(15):1375-1382.
32. Sharma S.K., Ebadi M. Distribution kinetics of 18F-DOPA in weaver mutant mice. Brain Res. Mol. Brain Res. 2005, 139(1):23-30.
33. Sharma S.K. H, Ebadi M. Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull. 2006, 70(1):22-32.
34. Hume S.P., Lammertsma A.A., Myers R., Rajeswaran S., Bloomfield P.M., Ashworth S., et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J. Neurosci. Meth. 1996, 67(2):103-112.
35. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 2006, 30(1):26-35.
36. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47(4):493-503.
37. Yee R.E., Irwin I., Milonas C., Stout D.B., Huang S.C., Shoghi-Jadid K., et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov. Disord. 2001, 16(5):838-848.
38. Cohen R.M., Carson R.E., Aigner T.G., Doudet D.J. Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Res. 1998, 806(2):292-296.
39. Doudet D.J., Miyake H., Finn R.T., McLellan C.A., Aigner T.G., Wan R.Q., et al. 6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys. Exp. Brain Res. 1989, 78(1):69-80.
40. Guttman M., Yong V.W., Kim S.U., Calne D.B., Martin W.R., Adam M.J., et al. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse 1988, 2(5):469-473.
41. Strome E.M., Cepeda I.L., Sossi V., Doudet D.J. Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol. Imaging Biol. 2006, 8(5):292-299.
42. Hume S.P., Opacka-Juffry J., Myers R., Ahier R.G., Ashworth S., Brooks D.J., et al. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse 1995, 21(1):45-53.
43. Nikolaus S., Larisch R., Beu M., Forutan F., Vosberg H., Muller-Gartner H.W. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur. J. Nucl. Med. Mol. Imaging 2003, 30(3):390-395.
44. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 2002, 15(6):991-998.
45. Sanchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A.L., Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation 2004, 1(1):6.
46. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997, 38(3):389-398.
47. Nguyen T.V., Brownell A.L., IrisChen Y.C., Livni E., Coyle J.T., Rosen B.R., et al. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 2000, 36(1):57-65.
48. Lauwers E., Beque D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol. Aging 2007, 28(2):248-257.
49. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 2000, 23(10 Suppl):S2-S7.
50. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 2003, 54(1):93-101.
51. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287(13):1653-1661.
52. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J. Med. 2004, 351(24):2498-2508.
53. Jacobs A.H., Winkler A., Castro M.G., Lowenstein P. Human gene therapy and imaging in neurological diseases. Eur. J. Nucl. Med. Mol. Imaging 2005, 32(Suppl 2):S358-S383.
54. Leriche L., Bjorklund T., Breysse N., Besret L., Gregoire M.C., Carlsson T., et al. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J. Neurosci. 2009, 29(5):1544-1553.
55. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260(5111):1130-1132.
56. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350(6315):230-232.
57. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 2000, 886(1-2):82-98.
58. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 2000, 20(12):4686-4700.
59. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290(5492):767-773.
60. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380(6571):252-255.
61. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373(6512):335-339.
62. Kishima H., Poyot T., Bloch J., Dauguet J., Conde F., Dolle F., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol. Dis. 2004, 16(2):428-439.
63. Sullivan A.M., Opacka-Juffry J., Blunt S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur. J. Neurosci. 1998, 10(1):57-63.
64. Opacka-Juffry J., Ashworth S., Hume S.P., Martin D., Brooks D.J., Blunt S.B. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. NeuroReport 1995, 7(1):348-352.
65. Storch A., Hofer A., Kruger R., Schulz J.B., Winkler J., Gerlach M. New developments in diagnosis and treatment of Parkinson's disease-from basic science to clinical applications. J. Neurol. 2004, 251(Suppl 6):VI/33-VI/38.
66. Bjorklund L.M., Sanchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(4):2344-2349.
67. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002, 418(6893):50-56.
68. Lee S.H., Lumelsky N., Studer L., Auerbach J.M., McKay R.D. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat. Biotechnol. 2000, 18(6):675-679.
69. Carvey P.M., Ling Z.D., Sortwell C.E., Pitzer M.R., McGuire S.O., Storch A., et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp. Neurol. 2001, 171(1):98-108.
70. Schwarz S.C., Wittlinger J., Schober R., Storch A., Schwarz J. Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with cyclosporine A. Parkinsonism Relat. Disord. 2006, 12(5):302-308.
71. Bakay R.A., Raiser C.D., Stover N.P., Subramanian T., Cornfeldt M.L., Schweikert A.W., et al. Implantation of Spheramine in advanced Parkinson's disease (PD). Front. Biosci. 2004, 9:592-602.
72. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J. Med. 2001, 344(10):710-719.
73. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54(3):403-414.
74. Walczak P., Bulte J.W. The role of noninvasive cellular imaging in developing cell-based therapies for neurodegenerative disorders. Neurodegener. Dis. 2007, 4(4):306-313.
75. Brooks D.J. Positron emission tomography imaging of transplant function. NeuroRx 2004, 1(4):482-491.
76. Brownell A.L., Livni E., Galpern W., Isacson O. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann. Neurol. 1998, 43(3):387-390.
77. Chen Y.I., Brownell A.L., Galpern W., Isacson O., Bogdanov M., Beal M.F., et al. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. NeuroReport 1999, 10(14):2881-2886.
78. Hardy J. The shorter amyloid cascade hypothesis. Neurobiol. Aging 1999, 20(1):85. discussion 87.
79. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. 2001, 3(1):75-80.
80. Laws S.M., Hone E., Gandy S., Martins R.N. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J. Neurochem. 2003, 84(6):1215-1236.
81. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
82. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol. 2007, 20(4):398-402.
83. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(13):7737-7741.
84. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43(6):815-825.
85. Meguro K., Blaizot X., Kondoh Y., Le Mestric C., Baron J.C., Chavoix C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 1999, 122(Pt 8):1519-1531.
86. Millien I., Blaizot X., Giffard C., Mezenge F., Insausti R., Baron J.C., et al. Brain glucose hypometabolism after perirhinal lesions in baboons: implications for Alzheimer disease and aging. J. Cereb. Blood Flow Metab. 2002, 22(10):1248-1261.
87. Bhagat Y.A., Obenaus A., Richardson J.S., Kendall E.J. Evolution of beta-amyloid induced neuropathology: magnetic resonance imaging and anatomical comparisons in the rodent hippocampus. Magma 2002, 14(3):223-232.
88. Xiao-Chuan W., Zheng-Hui H., Zheng-Yu F., Yue F., Yun-Huang Y., Qun W., et al. Correlation of Alzheimer-like tau hyperphosphorylation and fMRI bold intensity. Curr. Alzheimer Res. 2004, 1(2):143-148.
89. Higgins G.A., Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav. Pharmacol. 2003, 14(5-6):419-438.
90. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9(7):532-544.
91. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55(3):306-319.
92. Toyama H., Ye D., Ichise M., Liow J.S., Cai L., Jacobowitz D., et al. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32(5):593-600.
93. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25(46):10598-10606.
94. Bacskai B.J., Hickey G.A., Skoch J., Kajdasz S.T., Wang Y., Huang G.F., et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(21):12462-12467.
95. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27(41):10957-10968.
96. Valla J., Chen K., Berndt J.D., Gonzalez-Lima F., Cherry S.R., Games D., et al. Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's Disease. Neuroimage 2002, 16(1):1-6.
97. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(9):3100-3105.
98. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 2006, 26(5):1343-1354.
99. Rudin M., Mueggler T., Allegrini P.R., Baumann D., Rausch M. Characterization of CNS disorders and evaluation of therapy using structural and functional MRI. Anal. Bioanal. Chem. 2003, 377(6):973-981.
100. Sykova E., Vorisek I., Antonova T., Mazel T., Meyer-Luehmann M., Jucker M., et al. Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(2):479-484.
101. Sun S.W., Song S.K., Harms M.P., Lin S.J., Holtzman D.M., Merchant K.M., et al. Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging. Exp. Neurol. 2005, 191(1):77-85.
102. Jack C.R., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., et al. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004, 52(6):1263-1271.
103. Lee S.P., Falangola M.F., Nixon R.A., Duff K., Helpern J.A. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn. Reson. Med. 2004, 52(3):538-544.
104. Vanhoutte G., Dewachter I., Borghgraef P., Van Leuven F., Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 2005, 53(3):607-613.
105. Jack C.R., Wengenack T.M., Reyes D.A., Garwood M., Curran G.L., Borowski B.J., et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 2005, 25(43):10041-10048.
106. Dhenain M., Privat N., Duyckaerts C., Jacobs R.E. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed. 2002, 15(3):197-203.
107. Anderson S.A., Frank J.A. MRI of mouse models of neurological disorders. NMR Biomed. 2007, 20(3):200-215.
108. Poduslo J.F., Wengenack T.M., Curran G.L., Wisniewski T., Sigurdsson E.M., Macura S.I., et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 2002, 11(2):315-329.
109. Wadghiri Y.Z., Sigurdsson E.M., Sadowski M., Elliott J.I., Li Y., Scholtzova H., et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 2003, 50(2):293-302.
110. Wengenack T.M., Jack C.R., Garwood M., Poduslo J.F. MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl 1):S82-S88.
111. Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., Saido T.C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 2005, 8(4):527-533.
112. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993, 187(2):433-437.
113. von Kienlin M., Kunnecke B., Metzger F., Steiner G., Richards J.G., Ozmen L., et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 2005, 18(1):32-39.
114. Mueggler T., Sturchler-Pierrat C., Baumann D., Rausch M., Staufenbiel M., Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 2002, 22(16):7218-7224.
115. Mueggler T., Baumann D., Rausch M., Staufenbiel M., Rudin M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2003, 23(23):8231-8236.
116. Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer's disease. Am. J. Med. 2007, 120(5):388-397.
117. Lichtlen P., Mohajeri M.H. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 2008, 104(4):859-874.
118. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740):173-177.
119. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408(6815):979-982.
120. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 2004, 24(28):6277-6282.
121. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6(8):916-919.
122. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(15):8850-8855.
123. Wisniewski T., Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 2005, 15(1):72-77.
124. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9(4):448-452.
125. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 2002, 16(8):860-862.
126. Sadowski M.J., Pankiewicz J., Scholtzova H., Mehta P.D., Prelli F., Quartermain D., et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(49):18787-18792.
127. Tuszynski M.H. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007, 21(2):179-189.
128. Tuszynski M.H. Nerve growth factor gene delivery: animal models to clinical trials. Dev. Neurobiol. 2007, 67(9):1204-1215.
129. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 2000, 10(3):381-391.
130. Aicardi G., Argilli E., Cappello S., Santi S., Riccio M., Thoenen H., et al. Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(44):15788-15792.
131. Williams L.R., Varon S., Peterson G.M., Wictorin K., Fischer W., Bjorklund A., et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc. Natl. Acad. Sci. U.S.A. 1986, 83(23):9231-9235.
132. Tuszynski M.H., U H.S., Amaral D.G., Gage F.H. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J. Neurosci. 1990, 10(11):3604-3614.
133. Williams L.R. Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp. Neurol. 1991, 113(1):31-37.
134. Isaacson L.G., Saffran B.N., Crutcher K.A. Intracerebral NGF infusion induces hyperinnervation of cerebral blood vessels. Neurobiol. Aging 1990, 11(1):51-55.
135. Winkler J., Ramirez G.A., Kuhn H.G., Peterson D.A., Day-Lollini P.A., Stewart G.R., et al. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol. 1997, 41(1):82-93.
136. Jonhagen M.E. Nerve growth factor treatment in dementia. Alzheimer Dis. Assoc. Disord. 2000, 14(Suppl 1):S31-S38.
137. Emerich D.F., Winn S.R., Harper J., Hammang J.P., Baetge E.E., Kordower J.H. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 1994, 349(1):148-164.
138. Chen K.S., Gage F.H. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J. Neurosci. 1995, 15(4):2819-2825.
139. Tuszynski M.H., Roberts J., Senut M.C., U H.S., Gage F.H. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 1996, 3(4):305-314.
140. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11(5):551-555.
141. Klein R.L., Hirko A.C., Meyers C.A., Grimes J.R., Muzyczka N., Meyer E.M. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res. 2000, 875(1-2):144-151.
142. Blesch A., Conner J., Pfeifer A., Gasmi M., Ramirez A., Britton W., et al. Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons. Mol. Ther. 2005, 11(6):916-925.
143. Tuszynski M., Thal L., Pay M., Tong G., Hoi-Sang U., Bakay R., et al. NGF gene therapy. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2006, 2(3):S50.
144. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., et al. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 2005, 26(7):995-1000.
145. Halagappa V.K., Guo Z., Pearson M., Matsuoka Y., Cutler R.G., Laferla F.M., et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2007, 26(1):212-220.
146. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25(12):3032-3040.
147. Vingtdeux V., Dreses-Werringloer U., Zhao H., Davies P., Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 2008, 9(Suppl 2):S6.
148. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 2005, 25(38):8807-8814.
149. Wang J., Ho L., Zhao Z., Seror I., Humala N., Dickstein D.L., et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006, 20(13):2313-2320.
150. Crouch P.J., White A.R., Bush A.I. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J. 2007, 274(15):3775-3783.
151. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002, 61(3):215-225. discussion 226-9.
152. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2):97-109.
153. Omuro A.M., Faivre S., Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 2007, 6(7):1909-1919.
154. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J. Med. 2005, 352(10):987-996.
155. Schaller B.J., Modo M., Buchfelder M. Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?. Mol. Imaging Biol. 2007, 9(2):60-71.
156. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64(19):6892-6899.
157. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007, 170(5):1445-1453.
158. Miller C.R., Perry A. Glioblastoma. Arch. Pathol. Lab. Med. 2007, 131(3):397-406.
159. Lang F.F., Miller D.C., Koslow M., Newcomb E.W. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 1994, 81(3):427-436.
160. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J. Med. 2005, 353(19):2012-2024.
161. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 1998, 90(19):1473-1479.
162. Cahill D.P., Levine K.K., Betensky R.A., Codd P.J., Romany C.A., Reavie L.B., et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 2007, 13(7):2038-2045.
163. Hunter C., Smith R., Cahill D.P., Stephens P., Stevens C., Teague J., et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006, 66(8):3987-3991.
164. Huse J.T., Holland E.C. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 2009, 19(1):132-143.
165. Fomchenko E.I., Holland E.C. Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 2006, 12(18):5288-5297.
166. Dai C., Holland E.C. Glioma models. Biochim. Biophys. Acta 2001, 1551(1):M19-M27.
167. Hu X., Holland E.C. Applications of mouse glioma models in preclinical trials. Mutat. Res. 2005, 576(1-2):54-65.
168. Raman V., Pathak A.P., Glunde K., Artemov D., Bhujwalla Z.M. Magnetic resonance imaging and spectroscopy of transgenic models of cancer. NMR Biomed. 2007, 20(3):186-199.
169. McConville P., Hambardzumyan D., Moody J.B., Leopold W.R., Kreger A.R., Woolliscroft M.J., et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin. Cancer Res. 2007, 13(10):2897-2904.
170. Herholz K., Coope D., Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 2007, 6(8):711-724.
171. Leenders W.P., Kusters B., Verrijp K., Maass C., Wesseling P., Heerschap A., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 2004, 10(18 Pt 1):6222-6230.
172. Leenders W., Kusters B., Pikkemaat J., Wesseling P., Ruiter D., Heerschap A., et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int. J. Cancer 2003, 105(4):437-443.
173. Claes A., Gambarota G., Hamans B., van Tellingen O., Wesseling P., Maass C., et al. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int. J. Cancer 2008, 122(9):1981-1986.
174. Veeravagu A., Hou L.C., Hsu A.R., Cai W., Greve J.M., Chen X., et al. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurol. Res. 2008, 30(9):952-959.
175. Kauppinen R.A. Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed. 2002, 15(1):6-17.
176. Chenevert T.L., McKeever P.E., Ross B.D. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin. Cancer Res. 1997, 3(9):1457-1466.
177. Hollingworth W., Medina L.S., Lenkinski R.E., Shibata D.K., Bernal B., Zurakowski D., et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am. J. Neuroradiol. 2006, 27(7):1404-1411.
178. Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar O, et al. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol;51(3):316-25.
179. Hakumaki J.M., Poptani H., Sandmair A.M., Yla-Herttuala S., Kauppinen R.A. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat. Med. 1999, 5(11):1323-1327.
180. Jacobs A.H., Dittmar C., Winkeler A., Garlip G., Heiss W.D. Molecular imaging of gliomas. Mol. Imaging 2002, 1(4):309-335.
181. Jacobs A.H., Kracht L.W., Gossmann A., Ruger M.A., Thomas A.V., Thiel A., et al. Imaging in neurooncology. NeuroRx 2005, 2(2):333-347.
182. Szeto M.D., Chakraborty G., Hadley J., Rockne R., Muzi M., Alvord E.C., et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009, 69(10):4502-4509.
183. Lyons S.K. Advances in imaging mouse tumour models in vivo. J. Pathol. 2005, 205(2):194-205.
184. Rehemtulla A., Stegman L.D., Cardozo S.J., Gupta S., Hall D.E., Contag C.H., et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000, 2(6):491-495.
185. Szentirmai O., Baker C.H., Lin N., Szucs S., Takahashi M., Kiryu S., et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006, 58(2):365-372. discussion 365-72.
186. Hsu A.R., Cai W., Veeravagu A., Mohamedali K.A., Chen K., Kim S., et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J. Nucl. Med. 2007, 48(3):445-454.
187. Dinca E.B., Sarkaria J.N., Schroeder M.A., Carlson B.L., Voicu R., Gupta N., et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J. Neurosurg. 2007, 107(3):610-616.
188. Adams J.Y., Johnson M., Sato M., Berger F., Gambhir S.S., Carey M., et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat. Med. 2002, 8(8):891-897.
189. Winkeler A., Sena-Esteves M., Paulis L.E., Li H., Waerzeggers Y., Ruckriem B., et al. Switching on the lights for gene therapy. PLoS ONE 2007, 2(6):e528.
190. Monfared P., Winkeler A., Klein M., Li H., Klose A., Hoesel M., et al. Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo. Cancer Res. 2008, 68(14):5932-5940.
191. Neves A.A., Brindle K.M. Assessing responses to cancer therapy using molecular imaging. Biochim. Biophys. Acta 2006, 1766(2):242-261.
192. Jacobs A., Voges J., Reszka R., Lercher M., Gossmann A., Kracht L., et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001, 358(9283):727-729.
193. Voges J., Reszka R., Gossmann A., Dittmar C., Richter R., Garlip G., et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 2003, 54(4):479-487.
194. Jacobs A.H., Rueger M.A., Winkeler A., Li H., Vollmar S., Waerzeggers Y., et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007, 67(4):1706-1715.
195. Miletic H., Fischer Y.H., Giroglou T., Rueger M.A., Winkeler A., Li H., et al. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin. Cancer Res. 2007, 13(22 Pt 1):6761-6768.
196. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
197. Cai W., Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front. Biosci. 2007, 12:4267-4279.
198. Cai W., Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49(Suppl 2):113S-128S.
199. Cairns R.A., Khokha R., Hill R.P. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr. Mol. Med. 2003, 3(7):659-671.
200. Zhang X., Xiong Z., Wu Y., Cai W., Tseng J.R., Gambhir S.S., et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J. Nucl. Med. 2006, 47(1):113-121.
201. Cao Q., Cai W., Li Z.B., Chen K., He L., Li H.C., et al. PET imaging of acute and chronic inflammation in living mice. Eur. J. Nucl. Med. Mol. Imaging 2007, 34(11):1832-1842.
202. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 1998, 4(5):623-626.
203. Hsu A.R., Hou L.C., Veeravagu A., Greve J.M., Vogel H., Tse V., et al. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol. Imaging Biol. 2006, 8(6):315-323.
204. Xiong Z., Cheng Z., Zhang X., Patel M., Wu J.C., Gambhir S.S., et al. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J. Nucl. Med. 2006, 47(1):130-139.
205. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279(5349):377-380.
206. Serganova I., Doubrovin M., Vider J., Ponomarev V., Soghomonyan S., Beresten T., et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res. 2004, 64(17):6101-6108.
207. Jacobs A., Dubrovin M., Hewett J., Sena-Esteves M., Tan C.W., Slack M., et al. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia 1999, 1(2):154-161.
208. Loo C., Lowery A., Halas N., West J., Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005, 5(4):709-711.
209. Reddy G.R., Bhojani M.S., McConville P., Moody J., Moffat B.A., Hall D.E., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res. 2006, 12(22):6677-6686.
210. van Tilborg G.A., Mulder W.J., Chin P.T., Storm G., Reutelingsperger C.P., Nicolay K., et al. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug. Chem. 2006, 17(4):865-868.
211. Sosnovik D.E., Schellenberger E.A., Nahrendorf M., Novikov M.S., Matsui T., Dai G., et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 2005, 54(3):718-724.
212. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
213. Laxman B., Hall D.E., Bhojani M.S., Hamstra D.A., Chenevert T.L., Ross B.D., et al. Noninvasive real-time imaging of apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(26):16551-16555.
214. Lee K.C., Hamstra D.A., Bhojani M.S., Khan A.P., Ross B.D., Rehemtulla A. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin. Cancer Res. 2007, 13(6):1839-1846.
215. Ray P., De A., Patel M., Gambhir S.S. Monitoring caspase-3 activation with a multimodality imaging sensor in living subjects. Clin. Cancer Res. 2008, 14(18):5801-5809.
216. Coppola J.M., Ross B.D., Rehemtulla A. Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin. Cancer Res. 2008, 14(8):2492-2501.
217. Messerli S.M., Prabhakar S., Tang Y., Shah K., Cortes M.L., Murthy V., et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 2004, 6(2):95-105.
218. Blankenberg F.G., Katsikis P.D., Tait J.F., Davis R.E., Naumovski L., Ohtsuki K., et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(11):6349-6354.
219. Mandl S.J., Mari C., Edinger M., Negrin R.S., Tait J.F., Contag C.H., et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol. Imaging 2004, 3(1):1-8.
220. Zhao M., Beauregard D.A., Loizou L., Davletov B., Brindle K.M. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 2001, 7(11):1241-1244.
221. Petrovsky A., Schellenberger E., Josephson L., Weissleder R., Bogdanov A. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 2003, 63(8):1936-1942.
222. Schellenberger E.A., Bogdanov A., Petrovsky A., Ntziachristos V., Weissleder R., Josephson L. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia 2003, 5(3):187-192.
223. Chang J., Ormerod M., Powles T.J., Allred D.C., Ashley S.E., Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000, 89(11):2145-2152.
224. Brekke C., Williams S.C., Price J., Thorsen F., Modo M. Cellular multiparametric MRI of neural stem cell therapy in a rat glioma model. Neuroimage 2007, 37(3):769-782.
225. Aboody K.S., Brown A., Rainov N.G., Bower K.A., Liu S., Yang W., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(23):12846-12851.
226. Benedetti S., Pirola B., Pollo B., Magrassi L., Bruzzone M.G., Rigamonti D., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat. Med. 2000, 6(4):447-450.
227. Ehtesham M., Kabos P., Kabosova A., Neuman T., Black K.L., Yu J.S. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 2002, 62(20):5657-5663.
228. Ehtesham M., Kabos P., Gutierrez M.A., Chung N.H., Griffith T.S., Black K.L., et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002, 62(24):7170-7174.
229. Barresi V., Belluardo N., Sipione S., Mudo G., Cattaneo E., Condorelli D.F. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. Cancer Gene Ther. 2003, 10(5):396-402.
230. Shah K., Bureau E., Kim D.E., Yang K., Tang Y., Weissleder R., et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann. Neurol. 2005, 57(1):34-41.
231. Staflin K., Honeth G., Kalliomaki S., Kjellman C., Edvardsen K., Lindvall M. Neural progenitor cell lines inhibit rat tumor growth in vivo. Cancer Res. 2004, 64(15):5347-5354.
232. Noble M., Dietrich J. Intersections between neurobiology and oncology: tumor origin, treatment and repair of treatment-associated damage. Trends Neurosci. 2002, 25(2):103-107.
233. Miletic H., Fischer Y., Litwak S., Giroglou T., Waerzeggers Y., Winkeler A., et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol. Ther. 2007, 15(7):1373-1381.
234. Bulte J.W., Kraitchman D.L. Monitoring cell therapy using iron oxide MR contrast agents. Curr. Pharm. Biotechnol. 2004, 5(6):567-584.
235. Modo M., Hoehn M., Bulte J.W. Cellular MR imaging. Mol. Imaging 2005, 4(3):143-164.
236. Zhang Z., Jiang Q., Jiang F., Ding G., Zhang R., Wang L., et al. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage 2004, 23(1):281-287.
237. Anderson S.A., Glod J., Arbab A.S., Noel M., Ashari P., Fine H.A., et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 2005, 105(1):420-425.
238. Arbab A.S., Pandit S.D., Anderson S.A., Yocum G.T., Bur M., Frenkel V., et al. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 2006, 24(3):671-678.
239. Fulci G., Breymann L., Gianni D., Kurozomi K., Rhee S.S., Yu J., et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(34):12873-12878.
240. Waerzeggers Y., Klein M., Miletic H., Himmelreich U., Li H., Monfared P., et al. Multimodal imaging of neural progenitor cell fate in rodents. Mol. Imaging 2008, 7(2):77-91.